PubMed:30566307 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/PubMed/sourceid/30566307","sourcedb":"PubMed","sourceid":"30566307","source_url":"https://www.ncbi.nlm.nih.gov/pubmed/30566307","text":"Anti-parkinsonian drugs today.\nThe current pharmacotherapeutic options for Parkinson's disease is described in this article. Newly formulations of levodopa developed to date. Levodopa / carbidopa intestinal gel (Duodopa) was approved recently in Japan. Duodopa permits to maintain plasma concentrations of levodopa at steady levels and prolongs ON time without dyskinesia. IPX066 is a newly developed oral formulation of levodopa, and launched in US. It contains both an immediate-release and a sustained-release levodopa component. Safinamide has an inhibitory activity of glutamate release and antagonism of sodium channel activity in addition to MAO-B inhibitor. Opicapone is a novel third generation COMT inhibitor. Rasagiline is a widely used MAO-B inhibitor in many countries. Clinical trials of the both agents are performed in Japan. Pimavanserin, a 5-HT2A inverse agonist, is the first and only medication approved by FDA for the treatment of psychosis associated with Parkinson's disease.","tracks":[]}